A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC

NCT00000735 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Ampligen

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)